CDKN2A expression was significantly higher among patients with T2-stage HNSCC than among patients with T3-and T4-stage HNSCC (Figure 1B), indicating that CDKN2A expression is high in early malignant tumours and low in advanced malignant tumours. Here, CDKN2A is linked to cancer.